Titre : Hepatocellular carcinoma and direct- acting antivirals: A never ending story?
link : Hepatocellular carcinoma and direct- acting antivirals: A never ending story?
Hepatocellular carcinoma and direct- acting antivirals: A never ending story?
Hepatocellular carcinoma and direct- acting antivirals: A never ending story?Vincenza Calvaruso* andAntonio Craxì Version of Record online: 24 MAY 2017 DOI: 10.1111/liv.13421
Liver International
Key Points
• The benefit of SVR is higher in patients without clinically significant portal hypertension
• HCC occurrence in patients with compensated cirrhosis is comparable to historical controls of patients who achieved SVR after interferon-based therapy.
• Patients who achieve SVR with DAAs had a lower risk of developing liver cancer than those patients whose HCV infection was not cured.
• Data available on patients with previous HCC do not show an increased risk of HCC recurrence and report a comparable rate of reappearance of cancer among DAA-treated and
untreated patients.
untreated patients.
Full Text
Link Provided By
Henry E. Chang via Twitter
Henry E. Chang via Twitter
May 26
Thus articles Hepatocellular carcinoma and direct- acting antivirals: A never ending story?
that is all articles Hepatocellular carcinoma and direct- acting antivirals: A never ending story? This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article Hepatocellular carcinoma and direct- acting antivirals: A never ending story? the link address https://newsaninpiration.blogspot.com/2017/05/hepatocellular-carcinoma-and-direct.html
0 Response to "Hepatocellular carcinoma and direct- acting antivirals: A never ending story?"
Post a Comment